Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
Rhea-AI Summary
Eli Lilly (NYSE: LLY) has announced upcoming presentations of preclinical data at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 25-30. The company will showcase two key developments:
1. LY4050784: A selective SMARCA2 inhibitor, developed in collaboration with Foghorn Therapeutics, showing synergistic activity when combined with chemotherapy, pembrolizumab, and KRAS inhibitors in SMARCA4 mutant cancers.
2. LY4066434: A pan-KRAS inhibitor demonstrating high selectivity over HRAS and NRAS, with robust anti-tumor activity in KRAS-mutant models, including in the CNS.
Both programs are currently in Phase 1 clinical trials.
Positive
- Two promising cancer drug candidates in Phase 1 trials
- Strategic collaboration with Foghorn Therapeutics for SMARCA2 inhibitor development
- LY4066434 shows effectiveness in CNS applications, expanding potential market reach
Negative
- Both drugs still in early Phase 1 trials, far from commercialization
- Only preclinical data available, no human trial results yet
News Market Reaction – LLY
In the trading session that priced this news, LLY declined 3.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
In an oral presentation, Lilly, in collaboration with Foghorn Therapeutics, will present new preclinical data for LY4050784, a selective inhibitor of SMARCA2, in combination with chemotherapy, pembrolizumab, and KRAS inhibitors in preclinical models of SMARCA4 mutant cancers. Preclinical data for LY4066434, a pan-KRAS inhibitor that is highly selective over HRAS and NRAS, will also be presented. Both programs are currently enrolling Phase 1 studies.
Details on presentations are below:
Presentation Title: LY4050784, a selective inhibitor of SMARCA2, demonstrates synergistic activity in combinations with pembrolizumab or KRAS inhibitors
Abstract Number: 3779
Session Date & Time: Monday, April 28, 2:30-4:30 p.m. CST
Session Title: Continuum of Innovation: Biological Therapeutic Agents
Presenter: Nathan Brooks
Presentation Title: LY4066434, an oral small molecule pan-KRAS inhibitor, demonstrates robust anti-tumor activity in KRAS-mutant models, including in the CNS
Abstract Number: 4375
Session Date & Time: Tuesday, April 29, 9 a.m.-12 p.m. CST
Session Title: RAS Inhibitors
Presenter: Hong Gao
For more information on Lilly's Oncology pipeline click here.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly's oncology pipeline, including therapies under development, and the timeline for future readouts, presentations, and other milestones relating to therapies under development and their clinical trials, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, or that any of these therapies will receive initial regulatory approval or approvals for additional indications, as applicable, or be commercially successful. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
Refer to: | Megan Talon; megan.talon@lilly.com; 463-209-1470 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-details-of-presentations-at-2025-american-association-for-cancer-research-aacr-annual-meeting-302409875.html
SOURCE Eli Lilly and Company